Pre-Made Eftansomatropin Alfa Biosimilar, Fusion Protein targeting GHR fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting GHBP/GHIP for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Eftansomatropin Alfa Biosimilar, Fusion Protein targeting GHR fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting GHBP/GHIP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Eftansomatropin alfa is a potential highly differentiated long-acting recombinant human growth hormone being developed as a more convenient and effective therapy for growth hormone deficiency (GHD). Eftansomatropin alfa contains hGH-hyFc (GX-H9) which is a recombinant human growth hormone prepared by fusing hybrid Fc to human growth hormone hGH. Like endogenous growth hormone, eftansomatropin alfa stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth.
| Products Name (INN Index) | Pre-Made Eftansomatropin Alfa Biosimilar, Fusion Protein targeting GHR fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting GHBP/GHIP |
|---|---|
| INN Name | eftansomatropin alfa |
| Target | GHR |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [GH1 (growth hormone 1, somatotropin, GH, GH-N, GHN, hGH- N, pituitary growth hormone)]1 – IGHG4 Fc (Fragment constant) |
| VD LC | Fusion – [GH1 (growth hormone 1, somatotropin, GH, GH-N, GHN, hGH- N, pituitary growth hormone)]1 – IGHG4 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Genexine (Seongnam South Korea) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GHR |
| Package |
